In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketing in Brief: Tiffany & Co.

This article was originally published in The Rose Sheet

Executive Summary

Tiffany & Co.: Augmenting Trueste fragrance line-up with Silkening Bath Collection including body lotion, body creme, powder, soap, and bath and shower gel in August. All of the auxilliary products are formulated with silk powder "to leave the skin luminous and silky," Tiffany said. Packaged in pearlescent bottles "that recall the luminous quality of the pearl," the line ranges in price from $25 for the bath soap and soap dish to $65 for the body creme. Tiffany said that distribution for the Trueste scent, currently available in 350 doors including Saks Fifth Avenue, Neiman Marcus and Lord & Taylor, will expand to 600 doors by year's end. The company also noted that a second Tiffany men's scent is in the planning stages. Tiffany for Men debuted in late 1989 ("The Rose Sheet" June 19, 1989, p. 7)..

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel